Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

References

• Antoňanzas F, Oliba J, Pinillos M, Juàrez C. Economic aspects of the new Spanish laws on pharmaceutical preparations. Eur. J. Health Econ.8, 297–300 (2007).
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoeconomics Outcomes Res.9, 65–83 (2009).
   PubMedGoogle Scholar
• Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy67, 149–165 (2004).
   PubMed Web of Science ®Google Scholar
• Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth14(2), 18–22 (2008).
   Google Scholar
• Seeley E. Maximising the benefits from generic competition. Euro. Observer.10(2), 9–11 (2008).
   Google Scholar
• Kanavos P. Generic policies: rhetoric vs. reality. Euro. Observer.10(2), 1–6 (2008).
   Google Scholar
• Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26(2), 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy7(3), 1–11 (2009).
   PubMedGoogle Scholar
• Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res.9(5), 475-484 (2009).
   PubMedGoogle Scholar
• Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J.28, 88–136 (2007).
   PubMed Web of Science ®Google Scholar
• Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA296(24), 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch. Intern. Med.167, 950–955 (2007).
   PubMed Web of Science ®Google Scholar
• Choudry M, Soran H, Ziglam H. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM101, 445–448 (2008).
   PubMed Web of Science ®Google Scholar
• Leaonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol.102, 2047–2056 (2007).
   PubMed Web of Science ®Google Scholar
• Hawkey C. Drugs that cause and heal peptic ulcer disease. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 17 (2009).
   PubMedGoogle Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat Group. Variations and increase use of statins across Europe: data from administrative databases. BMJ328, 385–386 (2004).
   PubMed Web of Science ®Google Scholar
• Barbui C, Hotopf M, Freemantle N et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst. Rev. (4), CD002791 (2000).
   Google Scholar
• Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am. J. Psychiatry157(3), 338–343 (2000).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry52(12), 1166–1174 (2005).
   Google Scholar
• Agüera-Ortiz L, Ramos Garcia I. Effectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder. Actas Esp. Psiquiatr.34(3), 153–161 (2006).
   Google Scholar
• Yu-Isenberg KS, Fontes CL, Wan GJ et al. Acute and continuation treatment adequacy with venlafaxine extended release compared with fluoxetine. Pharmacotherapy24(1), 33–40 (2004).
   Google Scholar
• Baldomero EB, Ubago JG, Cercós CL et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress. Anxiety22(2), 68–76 (2005).
   Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics27(5), 435–438 (2009).
   PubMed Web of Science ®Google Scholar
• Godman B, Vlahovic-Palcevski V, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 37 (2009).
   PubMedGoogle Scholar
• Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicol.105(Suppl. 1), 35 (2009).
   Google Scholar
• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ336, 2–3 (2008).
   PubMed Web of Science ®Google Scholar
• Björnsson E, Abrahssom H, Simrén M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol. Ther.24, 945–954 (2006).
   PubMed Web of Science ®Google Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a primary care setting. Int. J. Clin. Pract.61(1), 15–23 (2007).
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract.62, 480–484 (2008).
   PubMed Web of Science ®Google Scholar
• Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br. J. Clin. Pharm.64, 476–481 (2007).
   PubMed Web of Science ®Google Scholar
• Kastelein J, Akdim F, Stroes E et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N. Engl. J. Med.358(14), 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N. Engl. J. Med.358(14), 1504–1507 (2008).
   PubMed Web of Science ®Google Scholar
• Cipriani A, Santilli C, Furukawa TA et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst. Rev.2, CD006532 (2009).
   PubMed Web of Science ®Google Scholar
• Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med.148, 16–29 (2008).
   PubMed Web of Science ®Google Scholar
• Frisk P, Mellgren TO, Hedberg N et al. Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol.64, 1223–1229 (2008).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszabek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract.62, 76–87 (2008).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Neovius M, Hedberg N et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy DOI:10.1016/j.healthpol.2009.09.014’ (2009) (Epub ahead of print).
   Google Scholar
• Gandía-Moya MC. Do we primary care doctors improve our prescription of generic medicines after the intervention of the area pharmacist. Aten. Primaria37(7), 386–391 (2006).
   Google Scholar